Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Hybrid PET/MRI imaging in healthy unsedated newborn infants with quantitative rCBF measurements using 15O-water PET.

Andersen JB, Lindberg U, Olesen OV, Benoit D, Ladefoged CN, Larsson HB, Højgaard L, Greisen G, Law I.

J Cereb Blood Flow Metab. 2018 Jan 1:271678X17751835. doi: 10.1177/0271678X17751835. [Epub ahead of print]

PMID:
29333914
2.

Tackling tuberculosis in sub-Saharan Africa: EDCTP achievements and the road ahead.

Surette MA, Beattie P, Nyirenda T, Olesen OF.

Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1220-1229. doi: 10.5588/ijtld.16.0944.

PMID:
29297441
3.

European & Developing Countries Clinical Trials Partnership (EDCTP).

Olesen OF.

Hum Vaccin Immunother. 2018 Jan 2;14(1):14-16. doi: 10.1080/21645515.2017.1356649. Epub 2017 Nov 17. No abstract available.

4.

Increasing European Support for Neglected Infectious Disease Research.

Olesen OF, Ackermann M.

Comput Struct Biotechnol J. 2017 Jan 19;15:180-184. doi: 10.1016/j.csbj.2017.01.007. eCollection 2017. Review.

5.

Advocacy, partnership and political commitment for TB vaccine research.

Olesen OF, Chan S, Chappell J, Guo Y, Leite LC.

Tuberculosis (Edinb). 2016 Aug;99 Suppl 1:S26-9. doi: 10.1016/j.tube.2016.05.007. Epub 2016 Jun 16.

6.

Childhood tuberculosis: a unified response to a global problem.

Bassyouni H, Breugelmans JG, Surette M, Olesen O.

Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:54. doi: 10.5588/ijtld.15.0848. No abstract available.

PMID:
26564543
7.

Genesis of EDCTP2.

Zumla A, Makanga M, Nyirenda T, Beattie P, Olesen OF, Breugelmans JG, Aklillu E, Corrah T, Mgone C.

Lancet Infect Dis. 2015 Jan;15(1):11-3. doi: 10.1016/S1473-3099(14)71034-5. Epub 2014 Dec 2. No abstract available.

PMID:
25477021
8.

Calling on Europe to support operational research in low-income and middle-income countries.

Quaglio G, Ramsay A, Harries AD, Karapiperis T, Putoto G, Dye C, Olesen OF, Tomson G, Zachariah R.

Lancet Glob Health. 2014 Jun;2(6):e308-10. doi: 10.1016/S2214-109X(14)70218-9. Epub 2014 May 21. No abstract available.

9.

List-mode PET motion correction using markerless head tracking: proof-of-concept with scans of human subject.

Olesen OV, Sullivan JM, Mulnix T, Paulsen RR, Højgaard L, Roed B, Carson RE, Morris ED, Larsen R.

IEEE Trans Med Imaging. 2013 Feb;32(2):200-9. doi: 10.1109/TMI.2012.2219693. Epub 2012 Sep 19.

PMID:
23008249
10.

Analysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent.

Nwaka S, Ochem A, Besson D, Ramirez B, Fakorede F, Botros S, Inyang U, Mgone C, Adae-Mensah I, Konde V, Nyasse B, Okole B, Guantai A, Loots G, Atadja P, Ndumbe P, Sanou I, Olesen O, Ridley R, Ilunga T.

BMC Int Health Hum Rights. 2012 Jul 27;12:11. doi: 10.1186/1472-698X-12-11.

11.

Health research in Africa: getting priorities right.

Olesen OF, Parker MI.

Trop Med Int Health. 2012 Sep;17(9):1048-52. doi: 10.1111/j.1365-3156.2012.03027.x. Epub 2012 Jun 21. No abstract available.

12.

Methods for motion correction evaluation using 18F-FDG human brain scans on a high-resolution PET scanner.

Keller SH, Sibomana M, Olesen OV, Svarer C, Holm S, Andersen FL, Højgaard L.

J Nucl Med. 2012 Mar;53(3):495-504. doi: 10.2967/jnumed.111.095240. Epub 2012 Feb 13.

13.

The selection of experts evaluating health projects for the EU Sixth Framework Program.

Quaglio G, Guardabasso V, Olesen OF, Draghia-Akli R.

Z Gesundh Wiss. 2011 Oct;19(5):445-452. Epub 2011 Feb 8.

14.

Motion tracking for medical imaging: a nonvisible structured light tracking approach.

Olesen OV, Paulsen RR, Højgaard L, Roed B, Larsen R.

IEEE Trans Med Imaging. 2012 Jan;31(1):79-87. doi: 10.1109/TMI.2011.2165157. Epub 2011 Aug 18.

PMID:
21859614
15.

Research and capacity building for control of neglected tropical diseases: the need for a different approach.

Kariuki T, Phillips R, Njenga S, Olesen OF, Klatser PR, Porro R, Lock S, Cabral MH, Gliber M, Hanne D.

PLoS Negl Trop Dis. 2011;5(5):e1020. doi: 10.1371/journal.pntd.0001020. Epub 2011 May 31. No abstract available.

16.

European Union vaccine research--an overview.

Sautter J, Olesen OF, Bray J, Draghia-Akli R.

Vaccine. 2011 Sep 9;29(39):6723-7. doi: 10.1016/j.vaccine.2010.12.060. Epub 2010 Dec 31.

PMID:
21195799
17.

Research priorities for neglected infectious diseases in Latin America and the Caribbean region.

Dujardin JC, Herrera S, do Rosario V, Arevalo J, Boelaert M, Carrasco HJ, Correa-Oliveira R, Garcia L, Gotuzzo E, Gyorkos TW, Kalergis AM, Kouri G, Larraga V, Lutumba P, Macias Garcia MA, Manrique-Saide PC, Modabber F, Nieto A, Pluschke G, Robello C, Rojas de Arias A, Rumbo M, Santos Preciado JI, Sundar S, Torres J, Torrico F, Van der Stuyft P, Victoir K, Olesen OF.

PLoS Negl Trop Dis. 2010 Oct 26;4(10):e780. doi: 10.1371/journal.pntd.0000780. Review. No abstract available.

18.

Motion tracking in narrow spaces: a structured light approach.

Olesen OV, Paulsen RR, Højgaar L, Roed B, Larsen R.

Med Image Comput Comput Assist Interv. 2010;13(Pt 3):253-60.

PMID:
20879407
19.

Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas.

Dujardin JC, González-Pacanowska D, Croft SL, Olesen OF, Späth GF.

Trends Parasitol. 2010 Aug;26(8):395-403. doi: 10.1016/j.pt.2010.04.012. Epub 2010 Jun 9. Review.

PMID:
20538522
20.

Biomarkers for tuberculosis disease activity, cure, and relapse.

Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A.

Lancet Infect Dis. 2010 Feb;10(2):68-9. doi: 10.1016/S1473-3099(10)70003-7. No abstract available.

PMID:
20113972
21.

Tuberculosis research in the European union: past achievements and future challenges.

Lång H, Quaglio G, Olesen OF.

Tuberculosis (Edinb). 2010 Jan;90(1):1-6. doi: 10.1016/j.tube.2009.10.002. Epub 2009 Oct 31.

PMID:
19880350
22.

Perspectives for parasitology and parasitology networks in Europe.

Dupouy-Camet J, Olesen OF, Dei-Cas E, Loiseau PM, Mas-Coma S.

Trends Parasitol. 2009 Jul;25(7):293-5. doi: 10.1016/j.pt.2009.03.010. Epub 2009 Jun 17.

PMID:
19540165
23.

European Union conference on poverty-related diseases research.

Gryseels B, Zumla A, Troye-Blomberg M, Kieny MP, Quaglio G, Holtel A, Laang H, Romaris M, De Magistris MT, Nuez AN, Olesen OF, Ghalouci R, Lönnroth A.

Lancet Infect Dis. 2009 Jun;9(6):334-7. doi: 10.1016/S1473-3099(09)70129-X. No abstract available.

PMID:
19467472
24.

The European effort towards the development of mucosal vaccines for poverty-related diseases.

Medaglini D, Olesen OF, Rappuoli R.

Vaccine. 2009 May 5;27(20):2641-8. doi: 10.1016/j.vaccine.2009.02.070. Epub 2009 Mar 3. Review.

PMID:
19428873
25.

Vaccine adjuvants: scientific challenges and strategic initiatives.

Harandi AM, Davies G, Olesen OF.

Expert Rev Vaccines. 2009 Mar;8(3):293-8. doi: 10.1586/14760584.8.3.293. Review.

PMID:
19249971
26.

Biomarkers for tuberculosis disease activity, cure, and relapse.

Wallis RS, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A.

Lancet Infect Dis. 2009 Mar;9(3):162-72. doi: 10.1016/S1473-3099(09)70042-8. Review.

PMID:
19246020
27.

Human vaccine research in the European Union.

Olesen OF, Lonnroth A, Mulligan B.

Vaccine. 2009 Jan 29;27(5):640-5. doi: 10.1016/j.vaccine.2008.11.064. Epub 2008 Dec 6. Review.

PMID:
19059446
28.

Immunity against HIV/AIDS, malaria, and tuberculosis during co-infections with neglected infectious diseases: recommendations for the European Union research priorities.

Boraschi D, Abebe Alemayehu M, Aseffa A, Chiodi F, Chisi J, Del Prete G, Doherty TM, Elhassan I, Engers H, Gyan B, Harandi AM, Kariuki T, Kironde F, Kouriba B, Langhorne J, Laskay T, Medaglini D, Olesen O, Onyebujoh P, Palma C, Sauerwein R, Sibanda E, Steinhoff U, Tagliabue A, Thiel A, Vahedi M, Troye-Blomberg M.

PLoS Negl Trop Dis. 2008 Jun 25;2(6):e255. doi: 10.1371/journal.pntd.0000255.

29.

Association of the 5-HT2A receptor gene polymorphism 102T/C with ischemic stroke.

Olesen OF, Bennike B, Dam H, Mellerup E.

J Mol Neurosci. 2006;30(3):323-8.

PMID:
17401157
30.

The short/long polymorphism in the serotonin transporter gene promoter is not associated with panic disorder in a Scandinavian sample.

Olesen OF, Bennike B, Hansen ES, Koefoed P, Woldbye DP, Bolwig TG, Mellerup E.

Psychiatr Genet. 2005 Sep;15(3):159. No abstract available.

PMID:
16094247
31.

Comments on in vitro and in vivo studies of fluvoxamine-clozapine interaction.

Olesen OV, Linnet K.

J Clin Psychopharmacol. 2002 Oct;22(5):527-8. No abstract available.

PMID:
12352280
32.
33.

Molecular cloning of XTP, a tau-like microtubule-associated protein from Xenopus laevis tadpoles.

Olesen OF, Kawabata-Fukui H, Yoshizato K, Noro N.

Gene. 2002 Jan 23;283(1-2):299-309.

PMID:
11867237
34.
35.

Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring.

Olesen OV, Poulsen B, Linnet K.

Ther Drug Monit. 2001 Feb;23(1):51-5.

PMID:
11206044
36.
37.

Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons.

Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olesen OF, Lovestone S.

J Neural Transm (Vienna). 2000;107(10):1201-12.

PMID:
11129110
39.

[Monitoring of serum olanzapine during antipsychotic treatment].

Linnet K, Olesen OV.

Ugeskr Laeger. 2000 Sep 4;162(36):4802-5. Danish.

PMID:
10994377
40.

High density lipoprotein inhibits assembly of amyloid beta-peptides into fibrils.

Olesen OF, Dagø L.

Biochem Biophys Res Commun. 2000 Apr 2;270(1):62-6.

PMID:
10733905
41.

Citalopram and breast-feeding: serum concentration and side effects in the infant.

Schmidt K, Olesen OV, Jensen PN.

Biol Psychiatry. 2000 Jan 15;47(2):164-5.

PMID:
10664835
42.

Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine.

Licht RW, Olesen OV, Friis P, Laustsen T.

J Clin Psychopharmacol. 2000 Feb;20(1):110-2. No abstract available.

PMID:
10653223
43.
44.
45.

Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex.

Petersen K, Olesen OF, Mikkelsen JD.

Neuroscience. 1999;91(2):651-9.

PMID:
10366022
46.
48.

Serum concentrations and side effects in psychiatric patients during risperidone therapy.

Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K.

Ther Drug Monit. 1998 Aug;20(4):380-4.

PMID:
9712460
49.

Amyloid beta neurotoxicity in the cholinergic but not in the serotonergic phenotype of RN46A cells.

Olesen OF, Dagø L, Mikkelsen JD.

Brain Res Mol Brain Res. 1998 Jun 15;57(2):266-74.

PMID:
9675425
50.

Supplemental Content

Loading ...
Support Center